Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Ana Alfonso-Pierola, Marina Diaz Beya, Teresa Bernal, David Valcarcel, Montserrat Arnan, María Luz Amigo, Joaquin Sanchez-Garcia, Raúl Azibeiro Melchor, Blanca Xicoy, Fernando Ramos, Mar Tormo, Joan Bargay, Maria Teresa Cedena Romero, Leonor Arenillas, Jose Francisco Falantes, Ariane Unamunzaga, Lourdes Hermosin Ramos, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 3868.

https://doi.org/10.1182/blood-2025-3868

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Blood (2025) 146 (Supplement 1): 7624.

https://doi.org/10.1182/blood-2025-7624

Published: 2025

Journal Articles

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Sara Torres-Esquius, Maria Gabarros-Subira, Maria Eugenia Rivero, Guillermo Ramil López, Lucia García Mañó, Felix Lopez, Concepción Fernandez, Francesca Guijarro, Marina Díaz-Beyá, Marta Pratcorona Canela, Pamela Acha, Sandra Novoa Jáuregui, Esperanza Tuset, Laura Palomo, David Valcarcel, Francesc Bosch Albareda, Andres Jerez, Maria Julia Montoro

Blood (2025) 146 (Supplement 1): 4998.

https://doi.org/10.1182/blood-2025-4998

Published: 2025

Journal Articles

Beyond TP53: Molecular IPSS-genes multihit status revisited

Blood (2025) 146 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2025-2090

Published: 2025

Journal Articles

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

Blood (2025) 146 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2025-2085

Published: 2025

Journal Articles

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Blood (2025) 146 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2025-2084

Published: 2025

Journal Articles

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Blood (2025) 146 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2025-2083

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5231.

https://doi.org/10.1182/blood-2025-5231

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2024-204557

Published: 2024

Journal Articles

Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals

Manuel Jorge Fernández Villalobos, Javier Ortiz, Angela Figuera Alvarez, Carlos De Miguel, Almudena De Laiglesia, Virginia Pradillo Fernandez, Marina Diaz Beya, Jordi Esteve, Marta Polo, Mayte Olave, Maria del Mar Moles, Amparo Pimentel, Ramon Garcia-Sanz, Gabriela Rodriguez Macias

Blood (2024) 144 (Supplement 1): 4285.

https://doi.org/10.1182/blood-2024-209528

Published: 2024

Journal Articles

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Blood (2024) 144 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2024-205407

Published: 2024

Journal Articles

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 6167.

https://doi.org/10.1182/blood-2024-203130

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Blood (2024) 144 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2024-198114

Published: 2024

Journal Articles

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Luca Lanino, Saverio D'Amico, Giulia Maggioni, Najla H. Al Ali, Yu-Hung Wang, Carmelo Gurnari, Nico Gagelmann, Jan Philipp Bewersdorf, Somedeb Ball, Paola Guglielmelli, Manja Meggendorfer, Anthony M. Hunter, Anne Sophie Kubasch, Erica Travaglino, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Cristina Astrid Tentori, Alessandro Buizza, Elisabetta Sauta, Matteo Zampini, Elena Riva, Gianluca Asti, Mattia Delleani, Francesca Ficara, Armando Santoro, Claudia Sala, Daniele Dall'Olio, Lorenzo Dall'Olio, Tariq Kewan, Ilaria Carola Casetti, Hussein Awada, Blanca Xicoy, Vladan Vucinic, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Angela Consagra, David Sallman, Wolfgang Kern, Massimo Bernardi, Patrizia Chiusolo, Lorenza Maria Borin, Maria Teresa Voso, Lisa Pleyer, Laura Palomo, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Guillermo Garcia-Manero, Sanam Loghavi, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Nicolaus Kröger, Pierre Fenaux, Michaela Fontenay, Valeria Santini, Torsten Haferlach, Ulrich Germing, Eric Padron, Marie Robin, Francesco Passamonti, Eric Solary, Alessandro M. Vannucchi, Gastone Castellani, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2024-204826

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Beyond TP53: Molecular IPSS-genes multihit status revisited

Prognostic and therapeutic impact of FLT3 mutations and allelic burden in myelodysplastic syndromes and chronic myelomonocytic leukemia: Results from a multicenter cohort study

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Optimal Timing for Response Assessment in Acute Myeloid Leukemia Patients Treated with CPX-351 Induction: Real World Experience from 8 Spanish Hospitals

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only